Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

HER2 Ag:PrThr:Pt:Tiss:Ord:Immune stain

Known as: HER2:concentración arbitraria:punto en el tiempo:tejido, no especificado:ordinal:tinción inmunológica, HER2 Antigen:Presence or Threshold:Point in time:Tissue, unspecified:Ordinal:Immune stain, HER2 , Ag:PrThr:Pt:Tessuto:Ord:Colorazione immunologica 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Approximately 4% of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) present EGFR exon 20 in… Expand
Is this relevant?
2019
2019
9089Background: HER2 exon 20 mutation is a well-known oncogenic driver in non-small cell lung cancer (NSCLC) and its testing is… Expand
Is this relevant?
2019
2019
Abstract The aim of the present study was to investigate serum HER2 extracellular domain (ECD) as a putative surrogate marker of… Expand
Is this relevant?
2017
2017
Abstract The aims of this study were to assess the prognostic value of the HER2 exon 27 mutations in breast cancer patients… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2017
2017
Objective To study the effect of HER2 on morphology and migration of MCF10A human mammary epithelial cells and its mechanism… Expand
Is this relevant?
2015
2015
Purpose: To analyze the profile of annual recurrence rate (ARR) of patients with early breast cancer (BC) in Tunisia. Patients… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2013
2013
BACKGROUND Algorithms for quantitation of HER2 immunohistochemistry were developed for breast carcinoma, where the membranous… Expand
Is this relevant?
2009
2009
539 Background: An increased baseline sHER-2 concentration is an indicator of poor prognosis in the metastatic and adjuvant… Expand
Is this relevant?
2009
2009
e22082 Background: Currently, up to 20% of HER2 tests in breast cancer may be inaccurate. To address this situation, the 2007… Expand
Is this relevant?
2006
2006
6081 Background: Pts with H+ metastatic (M) ESBC have a high risk of relapse. T has been reported to reduce the risk of relapse… Expand
Is this relevant?